Chimeric Anti-CD37 Antibody HH1 Reducing Immunogenicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for B-cell malignancies, such as those targeting the CD20 antigen, have limitations, and there is a need for alternative antibodies that can effectively target CD37 to improve treatment options for B-cell malignancies like non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
Innovation Solution
Development of chimeric or humanized antibodies derived from the mouse monoclonal antibody HH1, specifically designed to bind to human CD37, which includes a variable heavy chain and light chain sequence, and are engineered to include human constant heavy and light chains, combined with a radionuclide like 212Pb for radioimmunotherapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If murine monoclonal antibody HH1 is used for radioimmunotherapy, then antigen binding and cytotoxicity are achieved, but immunogenicity and safety are compromised
Solution Approach 1:
The patent applies parameter changes by modifying the antibody structure from fully murine to chimeric (combining murine variable regions with human constant regions) and humanized versions. This structural parameter change reduces immunogenicity while preserving antigen binding capability, resolving the contradiction between therapeutic efficacy and safety.
Solution Approach 2:
The patent creates composite antibody structures by combining murine and human antibody regions. The chimeric antibody HH1 combines murine variable regions (for antigen binding) with human constant regions (for reduced immunogenicity), while humanized antibodies use only human framework regions with grafted CDRs. This composite approach resolves the contradiction between maintaining efficacy and reducing harmful immunogenic responses.
2Reliability
If existing anti-CD37 antibodies are used, then some therapeutic effect is achieved, but efficacy and safety need improvement
Solution Approach 1:
The patent systematically improves therapeutic efficacy by optimizing antibody parameters including affinity maturation, isotype selection (IgG1, IgG3), and structural engineering. The chimeric and humanized antibodies demonstrate enhanced antigen binding and cytotoxicity compared to previous anti-CD37 antibodies, directly addressing the need for improved treatment efficacy.
3Adaptability or versatility
If CD20-targeting therapies are used, then B-cell malignancies are treated, but alternative targets are needed to overcome therapy limitations
Solution Approach 1:
The patent develops universal anti-CD37 antibodies that can function through multiple mechanisms (ADCC, CDC, apoptosis induction) similar to CD20-targeting therapies. The chimeric and humanized antibodies provide versatile treatment options for various B-cell malignancies, addressing the need for alternative targets while maintaining therapeutic effectiveness.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The chimeric or humanized antibodies demonstrate enhanced antigen binding, antibody-dependent cell-mediated cytotoxicity, and biodistribution, offering a promising treatment approach for B-cell malignancies by selectively targeting CD37-positive cells with improved efficacy compared to existing therapies.
Implementation Method 1
combined with a radionuclide like 212Pb for radioimmunotherapy
Implementation Method 2
antibody molecules that bind to human CD37
Implementation Method 3
an anti-CD37 antibody may mediate antibody-dependent cell-mediated cytotoxicity (ADCC) to the target cell, which occurs after the Fc portion of the bound antibody is recognized by appropriate receptors on cytotoxic cells of the immune system
Implementation Method 4
after the antibody binds to the extracellular domain of the CD37 antigen, it may activate the complement cascade and lyse the targeted cell
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to chimieric or humanized antibodies derived from the mouse monoclonal antibody HH1. The applications of the present invention include therapeutic applications in which pharmaceutical compositions comprising the antibodies of the present invention or radioimmunoconjugates hereof are used for treating B-cell malignancies.